(Q37962333)

26 August 2017

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. (English)

1 reference

26 August 2017

Omar Khan

1

1 reference

PubMed ID

22124371

26 August 2017

Nicholas B La Thangue

series ordinal

2

1 reference

PubMed ID

22124371

26 August 2017

language of work or name

1 reference

29 November 2011

1 reference

Immunology & Cell Biology

26 August 2017

1 reference

26 August 2017

90

1 reference

26 August 2017

85-94

1 reference

26 August 2017

1

1 reference

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

26 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Chromatin control and cancer-drug discovery: realizing the promise

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Expression switching in the stevor and Pfmc-2TM superfamilies in Plasmodium falciparum.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

An increasingly complex code

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Acetylation and deacetylation of non-histone proteins

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

The critical role of the class III histone deacetylase SIRT1 in cancer

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

HDAC family: What are the cancer relevant targets?

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

HDAC2 regulates chromatin plasticity and enhances DNA vulnerability

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Histone deacetylases (HDACs): characterization of the classical HDAC family

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

HDAC6-p97/VCP controlled polyubiquitin chain turnover

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Histone deacetylases 9 and 10 are required for homologous recombination

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Histone deacetylase inhibitors and genomic instability

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Attenuated DNA damage repair by trichostatin A through BRCA1 suppression.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Histone deacetylase inhibitors induce mitotic slippage

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Apoptosis in cancer: key molecular signaling pathways and therapy targets.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Autophagic and apoptotic effects of HDAC inhibitors on cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

https://api.crossref.org/works/10.1038%2FICB.2011.100

1 reference

7 January 2021

Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Unfolded protein response in cancer: the physician's perspective

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Autophagy in cancer: good, bad, or both?

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

The STATs of cancer--new molecular targets come of age

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

STATs in cancer inflammation and immunity: a leading role for STAT3

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

A phosphorylation-acetylation switch regulates STAT1 signaling.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Histone deacetylases as regulators of inflammation and immunity.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

HDAC expression and clinical prognosis in human malignancies

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Histone deacetylase 1 mRNA expression in lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Targeting of HDAC8 and investigational inhibitors in neuroblastoma.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Differential expression of selected histone modifier genes in human solid cancers

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Biomarkers for predicting clinical responses to HDAC inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium [...]

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

A phase 2 study of vorinostat in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

A phase II study of depsipeptide in refractory metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Entinostat for treatment of solid tumors and hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.100

7 January 2021

Identifiers

DOI

10.1038/ICB.2011.100

1 reference

26 August 2017

1 reference

PubMed ID

22124371